We examined the incidence of herpes varicella-zoster virus (VZV) infection in 151 patients undergoing allogeneic BMT between August 1990 and September 1997 and who survived at least 3 months. Median follow-up was 17 (range 3.3-80.7) months. Herpes simplex virus antibody positive (HSV+) patients received aciclovir 1200 mg p.o. daily or 750 mg i.v. daily, in divided doses from day 0 to engraftment. Ganciclovir (5 mg/kg i.v. three times per week) was given in CMV+ patients (or if the donor was CMV+) from engraftment to day 84. Ganciclovir was continued or recommenced if a dose of greater than 20 mg of prednisone was used for the treatment of GVHD otherwise aciclovir was recommenced. In HSV+ patients not receiving ganciclovir, aciclovir 600 mg p.o. daily in divided doses was given until at least 6 months after BMT. Thirty-two patients developed VZV infection from 4.1 to 28 months after transplant. The estimated cumulative incidence of VZV was 13% (95% confidence interval 6-19%) at 12 months, 32% (22-42%) at 24 months and 38% (27-50%) at 28 months, with no further cases beyond that time. No patient developed VZV whilst receiving aciclovir or ganciclovir (P Ͻ 0.0001). However, there was a rapid onset of VZV following cessation of antiviral therapy (33% (20-46%) at 1 year post cessation). The presence of GVHD and the prior duration of antiviral prophylaxis were significant and independent risk factors for the development of VZV. Age, underlying disease, conditioning therapy or donor type were not. We conclude that 3-6 months of low-dose aciclovir and ganciclovir are effective at delaying the onset of VZV after allogeneic BMT, but may not affect the overall incidence of infection. Prolonged prophylaxis may be warranted in patients at high risk of infection, for example those patients with GVHD. Bone Marrow Transplantation Varicella-zoster virus (VZV) infection remains a major cause of morbidity and mortality in patients following bone marrow transplantation (BMT) with 18-52% of recipients developing clinically apparent infection. [1] [2] [3] [4] The majority of these infections have been demonstrated to be due to reactivation of pre-existing infection [1] [2] [3] [4] and are associated with a high rate of dissemination as approximately 23% of cases present as varicella, another 15% subsequently develop cutaneous dissemination and 5% develop visceral dissemination.
Varicella-zoster virus (VZV) infection remains a major cause of morbidity and mortality in patients following bone marrow transplantation (BMT) with 18-52% of recipients developing clinically apparent infection. [1] [2] [3] [4] The majority of these infections have been demonstrated to be due to reactivation of pre-existing infection [1] [2] [3] [4] and are associated with a high rate of dissemination as approximately 23% of cases present as varicella, another 15% subsequently develop cutaneous dissemination and 5% develop visceral dissemination. 1, 2, 5 In addition, BMT recipients are at high risk of VZV-related complications such as bacterial superinfection, scarring and post-herpetic neuralgia. 2, 6 The introduction of aciclovir has had a major impact on the treatment of herpes virus infections in the severely immunocompromised host and its efficacy and lack of toxicity has led to its routine use as prophylaxis against herpes simplex virus (HSV) reactivation. The median time for HSV reactivation is 8 days after allogeneic BMT with the period of highest risk coinciding with the post-transplant neutropenic phase prior to engraftment. 7, 8 Hence the use of aciclovir as HSV prophylaxis is usually restricted to this period.
In contrast to HSV, VZV reactivation occurs later with a median time of reactivation of 5 months following allogeneic BMT. 2, 3 High-dose oral and intravenous aciclovir has demonstrated efficacy in the treatment of episodes of recurrent VZV infection in the immunocompetent and immunocompromised host and is now the standard of care. By contrast, while aciclovir has been demonstrated to be highly effective in suppressing HSV, the role of antiviral suppression of VZV is not routinely practised, even in immunocompromised populations at risk of reactivation. Few studies have evaluated the role of prolonged antiviral suppression in the prevention of VZV infection after allogeneic BMT. The antiviral susceptibility of VZV to aciclovir is five to 10 times less than HSV and hence the literature describing aciclovir therapy for VZV has been largely confined to high doses of aciclovir, well in excess of those used for HSV prophylaxis. 9, 10 Clinical efficacy has been demonstrated in the treatment of episodes of primary and recurrent VZV infection in the immunocompetent host using high-dose oral therapy. 11 VZV reactivation has been shown to be suppressed successfully in patients after allogeneic BMT using oral aciclovir at daily doses of 1200 mg for 6 months. 9, 10 Of note, VZV reactivation was shown to occur rapidly upon cessation of prophylaxis such that the overall incidence of infection at 1 year remained unchanged. The role of prolonged prophylaxis of VZV infection with low-dose aciclovir is unknown.
The aim of this study was to review retrospectively the efficacy of low-dose oral aciclovir and/or intravenous ganciclovir prophylaxis in prevention of the reactivation of VZV in a population of adult allogeneic BMT recipients and to evaluate the risk factors for reactivation.
Patients and methods
Patients were eligible for this study if they underwent allogeneic BMT at the Royal Melbourne Hospital between August 1990 and September 1997 and survived more than 100 days. Of the 192 patients who underwent allogeneic BMT during this period, 151 survived more than 100 days. The clinical and microbiological records of all 151 patients were examined. Data were collected by chart review and by consulting with referring doctors and/or patients.
Pre-transplant factors reviewed included: age, sex, underlying disease, donor type, conditioning regimen used and pre-transplant VZV, HSV and cytomegalovirus (CMV) antibody status. Post-transplant data consisted of the clinical diagnosis of VZV, the use of aciclovir and ganciclovir as antiviral prophylaxis, the presence or absence of chronic graft-versus-host disease (GVHD) and the use of immunosuppressive drugs.
VZV infection was defined as the presence of the characteristic vesicular skin lesions on an erythematous base and/or healing with crusts in a dermatomal or generalized cutaneous distribution. The diagnosis of VZV was made using clinical criteria in all cases. In a minority of cases there was microbiological and/or histological confirmation of infection. Post-herpetic neuralgia was defined as dermatomal pain that persisted beyond rash healing.
Patients received conditioning regimens as outlined in Table 1 . GVHD prophylaxis consisted of intravenous cyclosporin (3 mg/kg/day) and short course intravenous methotrexate (15 mg/m 2 day 1, 10 mg/m 2 days 3, 6 and 11). Cyclosporin was tapered at a time after engraftment according to the risk of disease relapse. 12 Patients were nursed in protective isolation during the period of neutropenia. Fluconazole (400 mg/day) was used as fungal prophylaxis from day 0 for 3 months or until the prednisone dose was less than 20 mg/day. Trimethoprim/sulfamethoxazole was used as prophylaxis against Pneumocystis carinii pneumonia from engraftment for 12 months or until after steroids had been ceased.
As antiviral prophylaxis, HSV+ patients received aciclovir 1200 mg p.o. or 750 mg i.v. daily, in divided doses three times a day 8 hourly from day 0 to engraftment. In CMV+ patients and CMV− patients with CMV+ donors, ganciclovir (5 mg/kg i.v. three times a week) was given from engraftment to at least day 84. 13 Ganciclovir was continued or recommenced if more than 20 mg of prednisone was used for treatment of GVHD. In patients not receiving ganciclovir, aciclovir 200 mg p.o. three times daily was given from day 0 until at least 6 months after BMT. In those patients receiving ganciclovir, it was recommended that aciclovir be recommenced at the completion of ganciclovir prophylaxis (usually day 84). Prophylaxis with Acute leukemia refers to acute lymphoblastic or acute myeloid leukemia or refractory anemia with excess blasts. CML = chronic myeloid leukemia; HLA = human leukocyte antigen; Cy = cyclophosphamide; Bu = busulphan; TBI = total body irradiation; VZV = varicella-zoster virus; HSV = herpes simplex virus; CMV = cytomegalovirus.
aciclovir was continued beyond 6 months at the physician's discretion in patients requiring ongoing immunosuppression for GVHD. GVHD was treated with prednisone and cyclosporin initially but further immunosuppressive therapy (antithymocyte globulin, tacrolimus and/or thalidomide) was given as required for management of steroid-resistant disease.
Statistical methods
Data were analyzed with a closing date of 1 January 1998 at which time 97 (64%) of the patients remained alive. Patients were censored at the time of death or at the time of most recent review. Median follow-up was 17 months (3.3-81 months).
The cumulative incidence of VZV infection was estimated using the Kaplan-Meier product limit method. To estimate the median time to onset of VZV conditional on developing VZV in the period under study, the time point at which the estimated cumulative incidence curve reached 50% of its maximum value was selected. This method of estimation avoids bias due to censored observations. A Cox proportional hazards regression model was used to determine the statistical significance of the administration of aciclovir or ganciclovir in preventing VZV. A time-dependent covariate was used which assumed the value 1 for all times at which either aciclovir or ganciclovir was administered and the value 0 at all remaining times.
In this study, no patient developed VZV while on aciclovir or ganciclovir, thus the periods of time when patients were on either of these drugs provided no information on the prognostic significance of other factors influencing the incidence of VZV. The significance of these other factors was thus studied in the data set obtained by excluding all periods on aciclovir or ganciclovir. Patients entered or exited the risk set according to the dates of cessation or commencement of aciclovir or ganciclovir, respectively.
The following factors were studied for their prognostic significance in determining the development of VZV following BMT: the presence of GVHD, the use of TBI in the conditioning regimen, underlying disease, donor-type, treatment with cyclosporin and/or prednisone and the prior duration of antiviral therapy. The Cox proportional hazards model was used to estimate the relative rates of developing VZV (hazard ratios) for various values of each factor. The prognostic significance was determined by the likelihood ratio test, using two-tailed significance levels. To determine the significance of administration of cyclosporin and/or prednisone, a time-dependent covariate was used which assumed the value 1 when the patient was on either or both drugs and 0 elsewhere. The prior duration of antiviral therapy was also studied using a time dependent covariate.
Stepwise regression methods were used for the multifactor analyses, using a forward selection procedure and determining which factors would enter or leave the model based on the change in the likelihood function. As no dates of development of graft-versus-host disease (GVHD) were available for analysis, it was assumed patients with GVHD had it from the day of BMT.
To determine the interval between cessation of antiviral therapy and the development of VZV, the period of time following cessation of the first period of administration of drug was studied, censoring the data at the point at which either VZV was diagnosed or aciclovir or ganciclovir was recommenced or the patient ceased to be followed up.
Throughout the report 95% confidence intervals (95% CI) have been given for the major results. No corrections have been made for multiple comparisons.
Results
The pre-transplant characteristics of the 151 patients are shown in Table 1 .
Incidence and timing of VZV infection
VZV infection was documented in 32 patients, the median age of which was 38.5 (range 17-55) years. Pre-transplant VZV serology was either positive (30 cases) or not tested (two cases).
The estimated cumulative incidence rose from 13% (95% CI: 6%-19%) at 1 year after allogeneic BMT, to 32% (95% CI: 22%-42%) at 2 years and plateaued at 38% (95% CI 27%-50%) at 2 years and 4 months, with no further cases diagnosed beyond that time (Figure 1 ). For those patients in whom VZV was documented, the time of onset ranged Bone Marrow Transplantation from 4.1 to 28 months post transplant, with an estimated median of 16 months conditional on developing VZV in the time period under study. VZV infection occurred at the diagnosis of relapse in one patient. All other patients were in remission.
Distribution
The distribution of VZV reactivation is shown in Table 2 . Of the 30 patients presenting with dermatomal VZV infection, seven had multiple, non-contiguous dermatomes involved. No episode of visceral dissemination was recorded.
Treatment of VZV infection with antiviral medication
All except one patient received antiviral therapy. Eleven patients were treated with intravenous aciclovir, 14 with oral aciclovir, four with famciclovir and two with valaciclovir. Twelve patients were admitted to hospital for treatment.
Complications of VZV infection
Seven (22%) patients developed post-herpetic neuralgia. One patient with lumbar dermatomal VZV infection developed a polyradiculopathy resulting in leg weakness. One patient with lumbosacral involvement developed urinary retention. There were no ophthalmic complications despite the number of cases with trigeminal nerve involvement. One patient died at the time of VZV infection from concurrent gram-negative septicemia. There were no deaths directly attributable to VZV infection.
The effect of antiviral prophylaxis
During the period of study and prior to the onset of VZV where relevant, 115 (76%) of the 151 patients received both aciclovir and ganciclovir, 28 (19%) had aciclovir only, six (4%) had ganciclovir only and two (1%) had neither. The median duration of antiviral use was 5.2 months (range: 0-34 months).
No patient developed VZV infection whilst receiving aciclovir or ganciclovir prophylaxis (P Ͻ 0.0001).
Time to development of VZV after cessation of first episode of aciclovir/ganciclovir
Only 121 cases were studied in this analysis: 28 of the 151 cases were excluded because they were on aciclovir or ganciclovir for the entire time they were followed up and a further two cases were excluded because they received neither aciclovir nor ganciclovir at any time.
Twenty-one of the remaining 121 patients developed VZV infection in the time period under study as indicated in Figure 2 . These cases were those developing VZV after cessation of the first continuous period of antiviral prophylaxis only. Patients who restarted aciclovir or ganciclovir after a break were analysed until the point they recommenced prophylaxis at which point they were censored. dence rose from 33% (95% CI 20%-46%) at 1 year after ceasing aciclovir or ganciclovir, to 42% (27-57%) at 2 years, with no case diagnosed beyond that time.
Risk factors for VZV infection
The results from a unifactor analysis of factors studied for their prognostic significance in determining the time to development of VZV are summarized in Table 3 . On unifactor analysis, the presence of GVHD, use of cyclosporin and/or steroids and the prior duration of antiviral therapy were significant risk factors for VZV reactivation. The risk of VZV infection increased as the previous duration of prophylactic antiviral therapy increased.
On multifactor analysis, GVHD and the prior duration of antiviral therapy remained significant (Table 4) . After adjusting for GVHD and the prior duration of antiviral therapy, the concomitant use of cyclosporin and/or steroids was not a statistically significant independent risk factor for the development of VZV infection. The cumulative incidence curves of VZV infection in patients with and without GVHD are shown in Figure 3 and according to the duration of previous antiviral therapy in Figure 4 . These two Figures are based on the period following the first cessation of antiviral therapy and illustrate risks to patients while they are not receiving such therapy.
Discussion
The results of this study demonstrate that low-dose aciclovir and/or ganciclovir used for at least 6 months after allogeneic BMT prevents VZV infection during the period of antiviral prophylaxis. This strategy delayed the onset of infection but did not, however, reduce the overall incidence of VZV infection in comparison with other series. [1] [2] [3] [4] [5] [6] 10, 14 In patients who received prophylaxis, the cumulative incidence of viral reactivation rose to 42% at 2 years after the cessation of antiviral therapy. VZV infection occurred rapidly after cessation of prophylaxis with almost one quarter of the cases occurring within 5 weeks of cessation of antiviral therapy.
Typically VZV infection occurs after engraftment with the period of greatest risk being between 2 and 10 months after BMT. 2, 3, 6 The majority (69-91%) of cases occur within the first year after BMT. A persistent susceptibility to reactivation of varicella, however, continues for up to 2 years but rarely (2-14%) thereafter. [1] [2] [3] [4] [5] [6] In the present series, during a period of antiviral prophylaxis continuing for at least 6 months post BMT using either low-dose aciclovir or ganciclovir, no VZV infections occurred. The overall rate of VZV infection was comparable to other reported studies but the estimated median time of onset of VZV reactivation was 16 months. This is much later than the previously reported median time of 5-7 months without prolonged antiviral prophylaxis and sug- gests that the use of prophylactic antiviral therapy delays the onset of VZV reactivation. It has been demonstrated previously that either clinical or subclinical reactivation is necessary for reconstitution of immunity to VZV following BMT. 10, 15 It is thus likely that suppression of VZV by antiviral prophylaxis in this study delayed the reactivation and hence immune response to VZV, resulting in later reactivations. Although 22% of patients suffered VZV infection in noncontiguous dermatomes, only 6% had evidence of cutaneous dissemination and there was no visceral dissemination or mortality attributable to VZV. This is in contrast to previous studies in which prolonged antiviral suppression was not used and in which cutaneous and visceral dissemination rates of 23-36% and VZV-related mortality rates of 8-12% were reported. 2, 3 As the overall incidence of reactivation was no different, it is likely that the markedly reduced rates of dissemination and VZV-related mortality were due to the suppression of reactivation to a later time when immune reconstitution was sufficiently established to contain a VZV reactivation. This is further supported by previous studies that demonstrated that the most serious VZV infections (visceral or central nervous system VZV) occurred during the first 6-9 months after allogeneic BMT. [1] [2] [3] It is also possible that the prompt use of antiviral agents to treat VZV infection after BMT results in a reduced incidence of dissemination and death. In a recent study 1 in which 76% of patients with established VZV infection received treatment with aciclovir, overall dissemination occurred in 18%, yet the rate of visceral dissemination was only 5% and mortality rate only 1%. Years off aciclovir/ganciclovir Number at risk Various risk factors have been identified previously as conferring a risk of VZV infection. These include age greater than 10 years, a diagnosis of leukemia and the use of TBI as part of conditioning regimens.
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1,2 GVHD has been identified as a risk factor for VZV in some studies, where it was particularly associated with the development of disseminated disease and death, 2 but it was not associated with risk of VZV in others. 1 In this study, the risk of developing VZV infection, when assessed by multifactor analysis, was associated with the presence of GVHD and the duration of prophylactic antiviral therapy. This latter observation was unexpected but it may be that patients who were once at high risk of reactivation remain at a higher risk even after immunosuppression is reduced. The use of cyclosporin and/or steroids, while significant by unifactor analysis, was not statistically significant as an independent risk factor for the development of VZV in our series. This is most likely due to the use of immunosuppression being associated with GVHD. Donor type, underlying disease, or the use of radiation in the conditioning regimen was not associated with a risk of VZV infection.
Chronic GVHD has previously been associated with immunological abnormalities, [16] [17] [18] although in studies of lymphocyte proliferative and transformation responses to VZV after BMT, 10, 19 the presence of chronic GVHD had no significant effect on the immune response to VZV. The association of VZV infection in this study with chronic GVHD suggests that GVHD confers a risk that is independent of the use of immunosuppressive therapy, probably because GVHD itself is an immunosuppressive state.
This study demonstrated that prophylaxis with low-dose oral aciclovir (600 mg p.o. daily) or ganciclovir (5 mg/kg three times weekly) afforded complete protection against the reactivation of VZV during the period of administration. Two previous randomized controlled trials have demonstrated that aciclovir at a dose of 1200 mg/day is effective in preventing concurrent VZV reactivation after BMT. 9, 10 This is the first report of successful VZV suppression using low-dose aciclovir. The susceptibility of VZV to aciclovir is approximately 10-fold lower than HSV and even highdose aciclovir at 800 mg is only marginally adequate according to in vitro susceptibility assays. 20 The low dose of aciclovir in this study was chosen due to local restrictions limiting availability of long-term aciclovir suppression to this dose. Given the success of VZV prophylaxis, it is thus likely that incomplete viral suppression was able to prevent clinical disease.
A major concern of suboptimal dosing in an immunocompromised host is the emergence of antiviral resistance. This has previously been demonstrated in an animal model of HSV infection. 21 There were no clinical breakthroughs of VZV in this population, suggesting that even if there was selection for small subpopulations of aciclovir-resistant VZV, they were not clinically significant over the period of suppression used in this series. Whether longer periods of suppression can cause clinically significant resistance is unknown.
Our data demonstrate that ganciclovir has clinical activity in the suppression of VZV infection. In vitro studies have demonstrated ganciclovir to have a similar efficacy to aciclovir for the inhibition of VZV infection 22 and it has been demonstrated to have activity against VZV in animal models as well as in BMT patients. 23 This suggests that during periods of ganciclovir use for CMV prophylaxis, the additional use of aciclovir for VZV suppression is unlikely to be necessary.
In summary, VZV infection can be prevented with a minimum 6-month course of low-dose oral aciclovir or with i.v. ganciclovir given three times a week. Protection is only afforded during the period of administration, although it can delay infection to a stage where the patient may be immunologically better equipped to deal with it and complications are reduced. The use of antiviral suppression to prevent early infection in patients at increased risk is thus worthy of consideration. It is unknown whether more prolonged prophylaxis, given until effective cellular immunity is re-established, can further reduce or even totally abrogate excess susceptibility to VZV reactivation. This is an important question that should be addressed in prospective studies.
